Surgery and Tumors

  • Antonio Bolognese
  • Dominique Elias
Part of the Updates in Surgery book series (UPDATESSURG)


Surgery is the fundamental treatment option in most solid tumors, but it is no longer the sole therapeutic weapon available. Instead it needs to be integrated in a considerably more complex multidisciplinary strategy, with two main aims: — To guarantee recovery and increase the duration of survival through the control of the disease, not only at the local-regional level, but also in general — To guarantee good quality of life by means of the most conservative possible treatment which maintains organ function and a good image of the organism.


Circulate Tumor Cell Peritoneal Carcinomatosis Colorectal Liver Metastasis Colorectal Metastasis Oncologic Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wiggers T, Jeekel J, Arends JW et al (1988) No-touch isolation tecnique in colon cancer: a controlled prospective trial. Br J Surg 75(5):409–415PubMedCrossRefGoogle Scholar
  2. 2.
    Salsbury AJ (1975) The significance of the circulating cancer cell. Cancer Treat Rev 2(1):55–72PubMedCrossRefGoogle Scholar
  3. 3.
    Sugarbaker PH, Corlew S (1982) Influence of surgical techniques on survival in patients with colorectal cancer. Dis Colon Rectum 25(6):545–557PubMedCrossRefGoogle Scholar
  4. 4.
    Glaves D, Hubert RP, Weiss L (1988) Hematogenous dissemination of cells from human renal carcinomas. Br J Cancer 57: 32–35PubMedGoogle Scholar
  5. 5.
    Vlems FA, Ruers T J, Punt CJ et al (2003) Relevance of disseminated tumor in blood bone marrow of patients with solid epithelial tumors in perspective. EJSO 29:289–302PubMedCrossRefGoogle Scholar
  6. 6.
    Klein CA, Blankestein TJ, Schmidr-Kittler O et al (2002) Genetic heterogenecity of single disseminated tumour cells in minimal residual cancer. Lancet 360:689–699CrossRefGoogle Scholar
  7. 7.
    Fisher B, Fisher ER (1967) Barrier function of lymph node to tumor cells and erythrocytes. Cancer 20:1907–1913PubMedCrossRefGoogle Scholar
  8. 8.
    Isono K, Sato H, Nakayama K (1991) Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48(5):411–420PubMedCrossRefGoogle Scholar
  9. 9.
    Hermanek P, Altendorf A (1981) Classification of colorectal carcinomas with regional lymphatic metastases. Pathol Res Pract 173(1-2): 1–11PubMedGoogle Scholar
  10. 10.
    Hermanek P, Hutter RV, Sobin LH, Wagner G (1997) International Union Against Cancer. TNM atlas, IV edition. Springer, Berlin Heidelber New YorkGoogle Scholar
  11. 11.
    Hermanek P, Giegel P, Dworak O (1989) Two programs for examination of regional lymph nodes in colorectal carcinoma with regard to the new pN classification. Pathos Res Pract 185:867–872Google Scholar
  12. 12.
    Herrera L, Villareal JR (1992) Incidence of metastases from rectal adenocarcinoma in small lymph nodes detected by a clearing tecnique. Dis Colon Rectum 35(8):783–788PubMedCrossRefGoogle Scholar
  13. 13.
    Morikawa E, Yasutomi M, Shindou K et al (1994) Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis Colon Rectum 37(3):219–223PubMedCrossRefGoogle Scholar
  14. 14.
    Greenson JK, Isenhart CE, Rice R et al (1994) Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with longterm survival. Cancer 73(3):563–569PubMedCrossRefGoogle Scholar
  15. 15.
    Raj GV, Moreno JG, Gomella LG (1998) Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 82:1419PubMedCrossRefGoogle Scholar
  16. 16.
    Hayashi N, Ito I, Yanagisawa A et al (1995) Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345(8960): 1257–1259PubMedCrossRefGoogle Scholar
  17. 17.
    Lindemann F, Schlimok G, Dirschell P (1992) Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 340(8821):685–689PubMedCrossRefGoogle Scholar
  18. 18.
    Braun S, Pantel K, Muller P et al (2000) Cytokeratine-positive cells in bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRefGoogle Scholar
  19. 19.
    Hosh SB, Braun S, Pantel K (2001) Characterization of disseminated tumor cells. Sem Surg Oncol 20:267–271Google Scholar
  20. 20.
    Hansen R, Wolf N, Knuechel R et al (1995) Tumor cells on blood shed from the surgical field. Arch Surg 130:387–393PubMedGoogle Scholar
  21. 21.
    Yamamoto K, Murae M, Yasuda M (1991) RGD-Containing peptides inhibit experimental peritoneal acceding of human ovarian cancer cells. Nippon Sanka Fujinka Gakkai Zasshi 43(12): 1687–1692PubMedGoogle Scholar
  22. 22.
    Elias D, Gachot B, Bonvallot S et al (1997) Peritoneal carcinosis treated by complete excision and immediate postoperative intraperitoneal chemotherapy. Phase II study in 54 patients. Gastroenterol Clin Biol 21(3): 181PubMedGoogle Scholar
  23. 23.
    Elias D, Cavalcanti A, Sabourin JC et al (1998) Results of 136 curative hepatectomies with a safety margin of less than 10mm for colorectal metastases. J Surg Oncol 69:88–93PubMedCrossRefGoogle Scholar
  24. 24.
    Koo J, Fung K, Siu KF et al (1983) Recovery of malignant tumor cells from the right atrium duting hepatic resection for hepatocellular carcinoma. Surgery 52:1952–1956Google Scholar
  25. 25.
    Slade NS, Simmons RL, Yunis E (1975) Immunodepression after major surgery in normal patients. Surgery 78:363–372PubMedGoogle Scholar
  26. 26.
    Elias D, Farace F, Triebel F et al (1995) Phase I-II randomized study on pre-hepatectomy recombinant inerleukin-2 in patients with metastasis carcinoma of the colon and rectum. J Am Coll Surg 181:303–310PubMedGoogle Scholar
  27. 27.
    Baker DG, Masterson TM, Pacer R et al (1989) The influence of the surgical wound on local recurrence. Surgery 106:525–532PubMedGoogle Scholar
  28. 28.
    Elias D, Lasser P, Rougier P et al (1987) Early adjuvant intraportal chemotheraphy after curative hepatectomy for colorectal liver metastases. A pilot study. Eur J Surg Oncol 13:247–250Google Scholar
  29. 29.
    Romano F, Cesana G, Berselli M et al (2004) Biological histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 88:240–247PubMedCrossRefGoogle Scholar
  30. 30.
    Elias D (1992) La chirurgie dite de réduction tumorale: mythe ou realité? J Chir (Paris) 129:479–483Google Scholar
  31. 31.
    André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRefGoogle Scholar
  32. 32.
    Moertel CG, Fleming TH, Mac Donald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected carcinoma. N Engl J Surg 322:352–358CrossRefGoogle Scholar
  33. 33.
    Elias D, Oueller JF (2001) Intraperitoneal chemohyperthermia. Rationale, technique, indication, and results. Surg Oncol Clin N Am 10:915–933PubMedGoogle Scholar
  34. 34.
    Verwaal VC, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hypertermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery with peritoneal carcinomatosis from colorectal cancer. J Clin Oncol 21:3737–3743PubMedCrossRefGoogle Scholar
  35. 35.
    Elias D, Sideris I, Pocard M et al (2004) Efficacy of intraperitoneal chemohypertermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 15:781–785PubMedCrossRefGoogle Scholar
  36. 36.
    Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064PubMedCrossRefGoogle Scholar
  37. 37.
    Peeters C, de Geus LF, Wetphal JR et al (2005) Decrease in circulating anti-angiogenic factor after removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 137:246–249PubMedCrossRefGoogle Scholar
  38. 38.
    Marie P, Cluner J (1910) Frequence des metastases viscérales chez les souri cancéreuses après ablation chirurgicale de leur tumeur. Bull Assoc Fr Etud Cancer 3:19–23Google Scholar
  39. 39.
    Buinauskas P, Mc Donald GO, Cole Wh (1958) Role of operative stress on the resistance of the experimental animal to inoculated cancer cells. Ann Surg 148:642–650PubMedCrossRefGoogle Scholar
  40. 40.
    Murthy MS, Scanlon EF, Reid JK, Yang XF (1996) Pre, peri and postoperative chemotherapy for breast cancer: is one better than the other? J Surg Oncol 61:273–277PubMedCrossRefGoogle Scholar
  41. 41.
    Elias D, Bonnay M, Puizzillou JM et al (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution and tolerance. Ann Oncol 13:267–272PubMedCrossRefGoogle Scholar
  42. 42.
    Elias D, Matsuhina T, Sideris L et al (2004) Heated intraoperative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15:1558–1565PubMedCrossRefGoogle Scholar
  43. 43.
    Elias D, Liberale G, Vernerey D et al (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic impact. Ann Surg Oncol 12:900–909PubMedCrossRefGoogle Scholar
  44. 44.
    Elias D, Youssef O, Sideris L et al (2004) Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4–9PubMedCrossRefGoogle Scholar
  45. 45.
    Weed DL, Greenwald P, Cullen JW (1990) The future of cancer prevention and control. Semin Oncol 17(4):504–509PubMedGoogle Scholar
  46. 46.
    Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 6(10):967–974PubMedGoogle Scholar
  47. 47.
    Folkman J (1997) Angiogenesis and angiogenesis inhibition: an overview. EXS 79:1–8PubMedGoogle Scholar
  48. 48.
    O’Relly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2(6):689–692CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Antonio Bolognese
    • 1
  • Dominique Elias
    • 2
  1. 1.Department of Surgery “P. Valdoni”University of Rome “La Sapienza”RomeItaly
  2. 2.Department of Surgical Oncology“Gustave-Roussy” InstituteVillejuifFrance

Personalised recommendations